Author:
Daugirdas Sarunas P.,Maatouk Christopher M.,Lai Hongxin J.,Ogidigben Miller J.,Singh Rishi P.
Abstract
Background and Objective:
Investigate central retinal thickness (CRT) variability and changes in best-corrected visual acuity (BCVA) after 12 months in patients with retinal vein occlusion (RVO) treated with dexamethasone intravitreal implants.
Patients and Methods:
Post hoc analyses of two randomized trials in patients with macular edema associated with branch or central RVO treated with a 0.7-mg dexamethasone implant. Central retinal thickness standard deviation (CRT-SD) and central retinal thickness amplitude (CRT-A) were measures of variability. Analyses included multinomial and simple linear regression.
Results:
In 400 patients, CRT-SD and CRT-A were significantly associated with central RVO, second dexamethasone implant, and baseline CRT. Baseline BCVA was associated with CRT-A. CRT-SD and CRT-A were significantly correlated with a 12-month change in BCVA (effect sizes of −0.032 and −0.013 letters/µm;
P
< 0.001). Patients in the highest CRT-SD quartile gained significantly fewer letters (+1.88 letters; 95% CI: −0.46 to 4.23).
Conclusion:
Greater CRT variability was associated with smaller BCVA improvements in patients with RVO treated with dexamethasone implants.
[
Ophthalmic Surg Lasers Imaging Retina
2024;55:XX–XX.]